ARB Selection Based on Comorbid Conditions in Hypertension
For patients with hypertension and specific comorbidities, ARB selection should be guided by compelling indications: use any ARB for chronic kidney disease with proteinuria or diabetes with nephropathy; use candesartan or valsartan specifically for heart failure with reduced ejection fraction; and use any ARB for coronary artery disease or post-stroke prevention when ACE inhibitors are not tolerated. 1, 2, 3
Chronic Kidney Disease (CKD) and Diabetic Kidney Disease
All ARBs are equally effective for renal protection in CKD. For patients with diabetic kidney disease or proteinuric CKD (urinary protein >150 mg/24 hours), initiate an ARB or ACE inhibitor as first-line therapy 1, 3. The specific ARB choice matters less than achieving adequate dosing—titrate to the higher end of the dose range when possible 1.
Dosing for Renal Protection:
- Candesartan: Start 16 mg daily, target 32 mg daily
- Irbesartan: Start 150 mg daily, target 300 mg daily
- Losartan: Start 25-50 mg daily, target 100 mg daily
- Valsartan: Start 80-160 mg daily, target 320 mg daily
- Telmisartan: Start 40 mg daily, target 80 mg daily
- Olmesartan: Start 20 mg daily, target 40 mg daily 1, 4
Critical caveat: Target blood pressure <130/80 mmHg in diabetic patients 3. Monitor potassium and creatinine closely, especially when combining with other RAAS inhibitors or in patients with GFR <45 mL/min 2, 4.
Heart Failure with Reduced Ejection Fraction (HFrEF)
Use candesartan or valsartan specifically—these are the only ARBs with proven mortality benefit in HFrEF 5, 6.
Heart Failure Dosing:
- Candesartan: Start 4-8 mg once daily, target 32 mg once daily
- Valsartan: Start 20-40 mg twice daily, target 160 mg twice daily 5
Important: ARBs are second-line to ACE inhibitors in HFrEF unless ACE inhibitors cause intolerable cough or angioedema 6, 2, 6. For patients with persistent symptoms despite optimal therapy (ACE inhibitor/ARB + beta-blocker + mineralocorticoid antagonist), consider switching to sacubitril-valsartan (ARNI) if ejection fraction <40%, potassium <5.2 mmol/L, and eGFR ≥30 mL/min/1.73 m² 2.
Do not combine ACE inhibitors with ARBs in HFrEF without heart failure specialist guidance—this increases hypotension, hyperkalemia, and worsening renal function without clear mortality benefit 2, 6.
Coronary Artery Disease (CAD)
Any ARB is acceptable for CAD when ACE inhibitors are not tolerated 6, 3, 6. The ONTARGET trial demonstrated telmisartan was non-inferior to ramipril in high-risk vascular disease patients 7, establishing ARBs as interchangeable with ACE inhibitors for coronary protection.
For stable angina, prioritize beta-blockers first, then add ARB or calcium channel blocker as needed 6. Avoid combining ACE inhibitor + ARB in CAD without heart failure—this combination showed no benefit and increased adverse events 6.
Preferred Combination for High-Risk CAD:
When combination therapy is needed in high-risk hypertensive patients with CAD, ACE inhibitor (or ARB) + dihydropyridine calcium channel blocker is superior to ACE inhibitor + diuretic based on the ACCOMPLISH trial showing 20% relative risk reduction in cardiovascular events 7, 6.
Post-Stroke/TIA
Use ACE inhibitor + thiazide diuretic as first-line after acute stroke phase 3. ARBs are second-line when ACE inhibitors are not tolerated. Target BP <140/90 mmHg after the acute phase 3.
Critical warning: Do not combine ACE inhibitor + ARB in stroke patients—the PRoFESS trial showed no benefit of telmisartan over placebo for recurrent stroke prevention 7, 3.
Diabetes Mellitus
For diabetic patients with cardiovascular or kidney disease (including microalbuminuria), use ACE inhibitor or ARB as initial therapy 3. Target BP <130/80 mmHg 3.
When combination therapy is needed, ACE inhibitor/ARB + dihydropyridine calcium channel blocker is preferred over ACE inhibitor/ARB + thiazide diuretic 3.
Left Ventricular Hypertrophy
Any first-line ARB is appropriate—ACE inhibitors, ARBs, long-acting calcium channel blockers, and thiazide diuretics all effectively reduce LVH 2. Avoid direct vasodilators (hydralazine, minoxidil) 2.
Practical Considerations
Race-Based Differences:
Black patients: Start with ARB + calcium channel blocker or ARB + thiazide diuretic rather than ARB monotherapy, as ARBs are less effective as monotherapy in this population 8, 9.
Comparative ARB Efficacy:
While guidelines treat ARBs as a class effect, real-world data suggests olmesartan and azilsartan may provide 1-2 mmHg greater BP reduction than losartan or valsartan 10, 11, 12. However, this modest difference is less clinically important than selecting the appropriate ARB for specific comorbidities and achieving target doses.
Monitoring Requirements:
- Check potassium and creatinine within 1-2 weeks of initiation or dose increase
- Avoid in bilateral renal artery stenosis (risk of acute renal failure) 4, 13
- If angioedema occurred with ACE inhibitor, wait 6 weeks before starting ARB and monitor closely—cross-reactivity is rare but possible 4, 5, 13
Contraindications:
Never combine ACE inhibitor + ARB + direct renin inhibitor—this triple RAAS blockade is potentially harmful 4, 13, 9.